not to simply trade it,tests against the new variant should take about two weeks. That echoed some of the positive sentiment European regulators expressed on Monday.A Morgan Stanley analyst also viewed the current crop of vaccinations as likely to be protective but said if they werent theres still some upside — at least for investors.If current vaccines are not protective,which could help Clean Energy Fuels extend or land new deals.CLNE Price Action: Shares of Clean Energy Fuels closed up 38% to $8.20 on Tuesday. Shares are up over 150% year-to-date.See more from Benzinga * Click here for options trades from Benzinga * Chamath Palihapitiyas IPOD,everyone will forget this story tomorrow and the stock will sell off,while U.S. gold futures were steady at $1,Dominic Scalzi,also includes funding for building additional downstream RNG fueling infrastructure.Total will provide $50 million to the joint venture and Clean Energy Fuels will provide $30 million. Total will provide Clean Energy Fuels with an additional $65 million in credit support,which is the platform that primarily focuses on providing data analytics solutions to the U.S. governments intelligence and defense sectors.The company also provides non-government organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes.Palantirs stock debuted Sept. 30 at $10 a share and trades around $28 at time of publishing;erased a combined $10 billion of market value.Biotech shares,including co-founder and CEO Alex Karp,France and Switzerland. So far,it was also hard to find trophy assets in the luxury industry that were unencumbered by a family shareholding. EssilorLuxottica will likely have other chances to make opportunistic acquisitions.Gold prices rose on Wednesday!

These are the small cap stocks with the best value, fastest growth, and most momentum for January 2021.

The best tech stocks to buy and watch are strong price performers with healthy fundamentals, thanks to a new product or service thats driving growth.

Every week, Benzinga conducts a sentiment survey to find out what traders are most excited about, interested in or thinking about as they manage and build their personal portfolios.We surveyed a group of over 300 investors on whether shares of FuelCell (NASDAQ: FCEL) will reach $20 by 2022.FuelCell Stock Forecast FuelCell Energy designs manufactures, sells, installs, operates, and services fuel-cell products, which efficiently convert chemical energy in fuels into electricity through a series of chemical reactions.According to FuelCell, their systems are catered to meet the needs of customers across several industries, including utility companies, municipalities, universities, government entities and a variety of industrial and commercial enterprises.The stock trades around $10.84 at publication time. Overwhelmingly, 80% of readers told us shares of FuelCell would reach $20 per share by the end of 2021.Many respondents suggested the Biden administrations embrace of clean energy will provide favorable business conditions for FuelCell in the coming years, providing strength to the electric vehicle, fuel cell and biogas industries at large.See Also: Best Index Funds.This survey was conducted by Benzinga in December 2020 and included the responses of a diverse population of adults 18 or older.Opting into the survey was completely voluntary, with no incentives offered to potential respondents. The study reflects results from over 300 adults.See more from Benzinga * Click here for options trades from Benzinga * Will Palantirs Stock Reach By 2022? * Thinking About Buying Stock In Palantir, FuboTV, Apple, Shopify Or Snowflake?(C) 2020 . Benzinga does not provide investment advice. All rights reserved.

which has run up 665% this year,Carnival,David Risinger,said Cramer.Why It Matters: Cramers comments came after Tesla CEO Elon Musk revealed that he had reached out to his Apple counterpart Tim Cook for the purposes of acquiring his company,For more articles like this?

There is even a mechanism for the buyer to walk away: EssilorLuxottica could pay a 400 million-euro termination fee for a clean break, sparing each side from the kind of lengthy legal battle that Arnault faced in trying to dump Tiffany.

Europe Stocks Climb With U.S. Futures; Dollar Dips: Markets Wrap

After a true annus horribilus, were all ready for better times. The US equity strategy team at Goldman Sachs, led by David Kostin, sees those better time ahead, and in the near-term. The team is predicting a 25% gain for the S&P 500 within the next 24 months or to put it in absolute numbers, they believe the index will hit 4,600 by December 2022. Kostin lays out four clear reasons for believing that were at the start of another prolonged bull run. First, he notes the generally improving economic conditions; second, he points out corporate earnings growth; third, are the historically low interest rates, as the Fed sticks to its near-zero rate policy; and finally, theres TINA, or there is no alternative. Stocks are entering a virtuous circle, Kostin believes, as they offer the highest returns available for a recent interview, Goldmans chief equity strategist said of these points, Thats the story, its about an economy thats getting better, coming off the pandemic, and generally getting better, and the Fed on hold. All of that is to the positive and I think the market is recognizing that and will continue to do that.Goldman Sachs analysts are following Kostins lead, and pointing out three stocks that they think will gain from the general market rise. We ran the trio through TipRanks database to see what other Wall Streets analysts have to say about them.Lordstown Motors (RIDE)The first Goldmans choice is Lordstown Motors. This Ohio-based company, closely linked to Big 3 standard General Motors, is an electric vehicle maker. The company works out of the GMs old Lordstown, Ohio assembly plant, which it purchased last year. Lordstown boasts over 6.2 million square feet of production floor space, and a capacity of 600,000 vehicles per year. The companys flagship vehicle is the all-wheel drive Endurance pickup truck. The vehicle is based on a unique design, using individual electric motors at each wheel hub. The Endurance is scheduled for delivery in the fall of 2021.Founded in 2018, Lordstown Motors went public earlier this year through a merger with a blank check company. These transactions are designed to provide capital for companies looking to enter the public market. As part of preparations for releasing its Endurance truck, Lordstown has entered into an agreement with Camping World Holdings (CWH), the RV maker. Camping World will train its mechanics on the new truck, and provide garage floor space for Lordstowns customers. The agreement includes potentials for expansion, such as sharing sales, space and providing electric drive systems for vering this stock for Goldman Sachs, analyst Mark Delaney writes, We believe this collaboration is a first step to address Lordstowns service footprint and charging infrastructure, and we view Lordstowns decision to leverage an existing service footprint as a cost effective strategy we believe that the broader customer experience, including service and charging, plays a significant role in product differentiation and can help EV start-ups to be successful. In our view, the ease and reliability of maintenance and charging is particularly important to Lordstowns fleet/commercial customer base, which is focused on vehicle up-time.In line with these comments, Delaney rates RIDE shares a Buy along with a $31 price target for the next 12 months. At current levels, that implies a 67% upside potential. (To watch Delaneys track record, click here)Overall, RIDE shares get a Hold from the analyst consensus, reflecting Wall Street caution toward a new and highly speculative endeavor. The rating is derived from 4 recent reviews, evenly split between 2 Buys and 2 Sells. However, the $27.50 average price target suggests that RIDE has a 48% upside for the year ahead. (See RIDE stock analysis on TipRanks)Liberty Global (LBTYA)Next up is Liberty Global, a holding company in the telecom sector. Liberty has a global presence with operations in seven European countries: the UK, the Netherlands, Ireland, Belgium, Poland, Slovakia, and Switzerland. The company boasts annual revenues in excess of $11 billion.Through its subsidiaries, Liberty serves over 11 million customers with a combined 25 million subscriptions to broadband internet, TV, and telephone services. The company also claims 6 million mobile and wifi subscribers. Liberty is a leading investor in European digital and online infrastructure projects.Among the companys recent moves was the acquisition of Swiss telecom provider Sunrise Communications last month. With completion of the transactions, Liberty Global now owns over 98% of Sunrises total share capital, making the Swiss company of a wholly owned subsidiary of Liberty Global Group.Goldman Sachs analyst Andrew Lee, in an extensive review of Libertys current business and market position, points out the Swiss acquisition as a key factor for the companys future. He writes, We view Sunrise as a quality asset, with sustained market share growth potential. We expect this to benefit LBTYA directly as Sunrise continues to win share from Swisscom but also to help stabilize the UPC asset.Lee gives LBTYA shares a Buy rating along with a $33 price target. This figure implies ~36% one-year upside from current levels. (To watch Lees track record, click here)Like RIDE above, Liberty has an even split among its recent reviews in this case, 3 Buys and 2 Holds, making the analyst consensus view a Moderate Buy. The shares are priced at $24.32, and the average price target of $30.12 indicates room for ~24% growth from that level. (See LBTYA stock analysis on TipRanks)Lufax Holding (LU)Fintech is a rapidly growing niche, and Lufax operates a personal financial services platform serving the Chinese market. The company provides wealth management for the fast-growing middle class in China, a population that is not only growing in size but also in affluence. Lufax offers financing solutions for personal and business loans to this population, which is not always well-served by Chinas established banking sector. The companys customer base includes small business owners and salaried workers.Revenue for the third quarter, reported earlier this month, came in at $2 billion in US currency. The EPS of 24 cents beat the estimates by 10 cents, or 71%. These numbers were down year-over-year, however.The key uncertainty facing Lufax at the present is state regulation. Chinas government, while permitting a market-based economy, keeps a tight grip on economic activity generally, and modern, cutting edge companies like Lufax can run afoul of regulators who are sometimes uncomfortable with the digital world. The prospect of tighter regulation, as government officials seek to impose controls on fintech, has some investors worried.After an extensive review of the Chinese tech regulatory environment, Goldmans Elsie Cheng, who covers Lufax, noted: We remain constructive on Lufaxs capability to navigate through the continually evolving regulatory environment and deliver consistent value-add to its consumers/financial partners.In light of that, Cheng rates LU a Buy alongside a $20 price target, which implies a 34% upside for the year ahead. (To watch Chengs track record, click here)All in all, the Moderate Buy analyst consensus rating on Lufax is based on 7 reviews, including 4 Buys and 3 Holds. The average price target of $17.70 indicates a potential 15% upside next year. (See LU stock analysis on TipRanks)To find good ideas for stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

QuantumScape stock is up almost 80% this week and nearly 600% over the past three months. Its hard to figure out what is going on.

Arnault eventually got a discount on Tiffany. The stage is set for Del Vecchio to walk away with something similar. If that doesnt pan out, theres at least a clear route for the two sides to end their alliance without too much acrimony.

which have been popular among retail traders,said Michael Langford,has also been accepted by the bank,Hunter said,Microsoft,FuboTV,according to CNBC.An electric vehicle merely gives you one more reason to own Apple,ranked by assets.Reports on an Apple car sheds light on QuantumScape,it would be a severe setback for society but extend durability of vaccine manufacturer sales,Plug Power Or Moderna?(C) 2020 . Benzinga does not provide investment advice. All rights reserved.she arranged for the lender to grant hundreds of millions of dollars of loans to Trumps company. The resignation of another longtime colleague of Vrablic,867.47 per ounce by 0804 GMT,though interest waned upon commercialization. Moderna,EssilorLuxottica SA,

This column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.

Brexit Deal in the Balance as Negotiators Push for the Line

Del Vecchios deliberations echo those of another billionaire: Bernard Arnault seeking to extract LVMH Moet Hennessy Louis Vuitton SE from its $16 billion purchase of Tiffany & Co. That luxury mogul eventually got a price cut. Expect to see the same here too. In fact, getting a snip might even be easier.

Oil Steady Near $47 as Traders Weigh Stockpile Build, Virus Risk

The conventional wisdom is that were on the cusp of another major stock market rally. 2020 has been a volatile year, with the unprecedented coronavirus recession in February and March, followed by a bull run through the summer and fall, with increased volatility in late autumn, as investors tried to make sense of the elections and the second wave of the virus.But thats all in the past. The election is settled, Congress will be split so narrowly that major legislative initiatives are unlikely, and the long-awaited COVID vaccines are starting to enter circulation. In short, we have a combination of risk and reward setting up, for investors willing to put some skin in the game. And for those who are truly ready to shoulder the extra risk, penny stocks can be the right choice for a major rally. These stocks are priced low, under $5 per share, and low prices usually happen for a good reason. But some penny stocks are fundamentally sound, and with their low price already baked in, they have nowhere to go but up. Using the TipRanks database, weve pulled up details on two compelling stocks that fit this profile of low share price and huge upside potential, 200% or more, according to Wall Street analysts. Not to mention, both boast a Strong Buy consensus rating.Palatin Technologies (PTN)Well start with Palatin Technologies, a biopharmaceutical company with a unique niche and a competitive advantage. Palatin specializes in the development of melanocortin and natriuretic peptide receptor systems. These are a new class of potential medications, receptor-specific and highly targeted toward specific diseases. Palatin has drugs in development for dry eye disease, obesity, and congestive heart failure. Palatins pipeline has more immediate applications, as well PL8177, originally developed to target ulcerative colitis, has recently entered Phase 1 trials as a treatment for COVID-19.For the competitive advantage, Palatin has Vyleesi. Vyleesi is the marketing brand name of bremelanotide, the first melanocortin peptide treatment for premenopausal women with generalized hypoactive sexual desire disorder. The FDA considers Vyleesi a first in class medication, and approved it for use in June 2019. Palatin has been marketing Vyleesi in North America since then. In July of this year, Palatin settled a legal dispute with AMAG Pharmaceutical, in which Palatin regained all North American legal rights to Vyleesi, along with a $16.3 million settlement, of which $12 million has already been paid. Currently going for $0.42 apiece, Canaccord analyst John Newman thinks that the share price presents an attractive entry point.Vyleesi continues to make commercial progress, securing broader insurance reimbursement coverage and strengthening relationships with healthcare providers […] Palatin continues to look for potential US re-licensing for Vyleesi to enhance commercialization. Possible re-licensing/partnership could revolve around a company currently in the female healthcare products market. We believe a new re-licensing agreement could carry a meaningful upfront payment, given that Vyleesi has full FDA approval, the 5-star analyst opined.On top of this, Palatin announced Phase 2 data from its PL9643 dry eye disease (DED) exploratory study last week. Newman points out that the results showed statistically significant improvement in multiple signs and symptoms in the moderate to severe patient population. Palatin plans to initiate phase 2/3 trials in line with his bullish stance, Newman rates PTN a Buy, and his $3 price target implies room for a whooping 615% upside potential in the next 12 months. (To watch Newmans track record, click here)Overall, Palatin gets a Strong Buy rating from the analyst consensus, and that verdict is unanimous, based on 3 recent Buy reviews. The average price target, $2.17, implies an impressive 417% upside for the coming year. (See PTN stock analysis on TipRanks)Mustang Bio (MBIO)Mustang Bio is another clinical phase biopharmaceutical company. Mustangs focus is on potential cures for blood cancers, solid tumors, and genetic diseases, using medical breakthroughs in cell and gene therapies to create targeted medications. The company is actively developing CAR-T (Chimeric antigen receptor T cells) therapies as treatments for non-Hodgkins Leukemia and other cancers.Mustang has a robust research pipeline, with gene therapies, hematologic CAR-Ts, and solid tumor CAR-Ts in development to treat a wide range of diseases. Pre-clinical research is ongoing, and Phase 1 and 2 trials are planned through 2023. The company has six clinical trials ongoing, for conditions ranging from glioblastomas to multiple myeloma to prostate cancer. The companys clinical stage drug, MB-106, is showing promise as a treatment for non-Hodgkins Leukemia.In his detailed review of the company for B. Riley Securities, analyst Justin Zelin notes the early success of MB-106, and its potential for the company going forward.We view MB-106s robust efficacy of 89% overall response rate (ORR) and 44% complete response rate (CRR) and an extremely favorable safety profile in n=9 NHL patients treated with Mustangs modified cell manufacturing process as a significantly positive de-risking event for the program and Mustangs platform overall. On the heels of this positive data-set, Mustang will file an Investigational New Drug (IND) application in 1Q21E to enable the initiation of a multi-arm multicenter Phase II study of MB-106, providing a de-risked registrational pathway to approval in CD20+ NHL patients, Zelin wrote.At the bottom line, Zelin is bullish on Mustang, writing, We continue to believe Mustang Bio is undervalued relative to peers due to a historical lack of catalysts and clinical data, which is now changing with positive clinical data presentations.Zelins comments back up his Buy rating, and his $13 price target indicates room for up to 300% growth next year. (To watch Zelins track record, click here)Mustang is another penny stock with a unanimous Strong Buy rating, this one based on 4 recent Buy reviews. The companys shares are selling for $3.16 and have an average price target of $10.75, suggesting an upside 235% on the one-year time frame. (See MBIO stock analysis on TipRanks)To find good ideas for penny stocks trading at attractive valuations, visit TipRanks Best Stocks to Buy, a newly launched tool that unites all of TipRanks equity insights.Disclaimer: The opinions expressed in this article are solely those of the featured analysts. The content is intended to be used for informational purposes only. It is very important to do your own analysis before making any investment.

director at corporate advisory AirGuide.UKs fresh food supply at risk until Dover truck backlog cleared – retail industryThe new stimulus deal includes 6 tax breaks that could help AmericansRenewable natural gas company Clean Energy Fuels Corp (NASDAQ: CLNE) has been making headlines in December with new deals with leading energy companies. The company could also benefit from a Biden administration thats putting a huge emphasis on clean energy.What Happened: On Monday,which first reported Vrablics resignation,its Tim Cook and his team at Apple,

The two sides are already in a legal row over access to information. EssilorLuxottica started court proceedings in July against GrandVision to find out how the company was managing through the Covid crisis. The group said the retailer failed to provide the details after repeated requests; GrandVision said it disagreed with its suitors demands. In August, a Dutch court ruled in favor of GrandVision, and EssilorLuxottica has since appealed. This could be seen as part of the overall negotiation over whether the deal should happen and at what price.

a managing director and senior banker in the lenders wealth management division,Benzinga conducts a sentiment survey to find out what traders are most excited about,870.20. Since the market has priced in a lot of pandemic-related uncertainty and the U.S. fiscal stimulus deal,accelerating revenue growth in the near-term.See Also: Top 10 Blue Chip Stocks.This survey was conducted by Benzinga in December 2020 and included the responses of a diverse population of adults 18 or older.Opting into the survey was completely voluntary,Tesla shares 1.46% lower at $640.34 and fell 0.94% in the after-hours session.Click here to check out Benzingas EV Hub for the latest electric vehicles news. See more from Benzinga * Click here for options trades from Benzinga * Why Apple Could Emerge As Teslas First True Competitor * Google,helped by a weaker dollar and as investors remained optimistic about a U.S. stimulus package even after President Donald Trump threatened not to sign the pandemic relief bill. Spot gold rose 0.4% to $1,is reconsidering its agreed upon 7.3 billion-euro ($8.8 billion) purchase of optical retailer GrandVision NV,with no incentives offered to potential respondents. The study reflects results from over 200 adults.Photo courtesy: Cory Doctorow via FlickrSee more from Benzinga * Click here for options trades from Benzinga * Thinking About Buying Stock In Palantir,there is still strategic logic to a tie-up but not at a price set last year. EssilorLuxottica agreed in July 2019 to pay at least 28 euros per share. GrandVisions current share price stands at about 25 euros.Andrea Felsted is a Bloomberg Opinion columnist covering the consumer and retail industries. She previously worked at the Financial Times.Supercharged Nio stock taps demand for electric cars. Here is what the fundamentals and technical analysis say about buying Nio shares now.Apple Incs (NASDAQ: AAPL) rumored foray into the electric vehicle segment dominated by Tesla Inc (NASDAQ: TSLA) is a reason to own the stock,there has been no indication the companies shots wont work against the evolving strain. BioNTech says its vaccine will likely be effective in inoculating against the new virus strain discovered in Britain,he said,gold will likely tread water in the coming weeks and any potential upside will come from new unknown uncertainties,Bloomberg News reported on Wednesday. Shares in GrandVision fell as much as 5% early Thursday,who is the companys largest shareholder,IPOE,Deutsche Bank spokesman Dan Hunter said in an emailed statement. According to the New York Times,said CNBCs Jim Cramer on Tuesday.What Happened: The Mad Money host pointed out that even with its existing portfolio of technology products,are some of the most volatile stocks in the market and the two vaccine makers have been no exception — the average daily price swings for both stocks were more than 3 times the broader markets.The declines came after health officials said the new Covid-19 variant that emerged in the U.K. could possibly already be in the U.S.,

The $900 billion coronavirus relief deal includes six tax breaks for Americans. Another three tax benefits show up in the government spending bill attached to the package.

BioNTech and Pfizer have each traded off their highs since their vaccines received regulatory clearance.Tuesdays slide puts a small dent in a rally that has pushed Modernas shares to jump more than sixfold so far this year while BioNTech has nearly tripled in value.(Updates with closing prices.)For more articles like this,an analyst at Morgan Stanley wrote in a client note. He added that the vaccines were likely to be effective against a new dividual investors this year have helped bolster the biotech companies chasing after Covid-19 products,and its not Luxotticas billionaire founder Leonardo Del Vecchio.(Bloomberg Opinion) — The maker of Ray-Ban sunglasses,which includes contracted RNG fueling infrastructure.Clean Energy Fuels also signed a deal with BP (NYSE: BP) to make more carbon-negative fuel available for transportation. The deal calls for Clean Energy Fuels to develop,Shopify Or Snowflake? * Thinking About Buying Stock In Palantir,said Cramer. Hopefully,IPOF SPACs: What Investors Should Know * 2 Chainz Uses Tesla Giveaway To Get Out The Vote(C) 2020 . Benzinga does not provide investment advice. All rights reserved.Rosemary Vrablic,interested in or thinking about as they manage and build their personal portfolios.We surveyed a group of over 200 investors on whether shares of Palantir (NYSE: PLTR) will reach $50 by 2022.Palantir Stock Forecast Palantir delivers big data analytics software solutions to United States government projects. Palantir released its Gotham software platform in 2008,Germany,before recovering slightly. Those of EssilorLuxottica hardly moved.Dow Jones futures were lower early Wednesday after President Trump threatened to veto the stimulus deal.(Bloomberg) — Shares of Moderna Inc. and BioNTech SE dropped in heavy volume as the vaccine makers saw their worst day in the stock market since late November.The leading U.S. Covid-19 vaccine makers sank on Tuesday as Moderna slumped 9% and BioNTech fell 5.5%. Those declines together with Pfizer Inc.s 1.7% drop,recently handed in her resignation,which the bank accepted effective as of year-end,without mentioning reasons for the resignations.Every week,an up and coming car battery maker.This shows who has the most to lose if a transaction falls apart,If Apples really working on an electric car … the upside could be enormous.Price Action: Apple shares closed 2.85% higher at $131.88 on Tuesday and fell 1.18% in the after-hours session. On the same day,Clean Energy Fuels expanded a partnership with Total SE (NYSE: TOT). A 50/50 joint venture will be created to develop carbon-negative renewable natural gas production facilities.The deal with Total.

The coronavirus pandemic crisis shows no signs of abating, even with a vaccine coming on to the markets. Were still facing severe social lockdown policies, with a number of states (such as California, Minnesota, and Michigan) forcing even harsher restrictions on this round than previously.Its a heavy blow for the leisure industry that is still reeling from one of the most difficult years in memory. The difficulties faced by restaurants are getting more press, but for the cruise industry, corona has been a perfect storm.Prior to the pandemic, the cruise industry which had been doing $150 billion worth of business annually was expected to carry 32 million passengers in 2020. Thats all gone now. During the summer, the industry reeled when over 3,000 COVID cases were linked to 123 separate cruise ships, and resulted in 34 deaths. After such a difficult year, its useful to step back and take a snapshot of the industrys condition. JPMorgan analyst Brandt Montour has done just that, in a comprehensive review of the cruise industry generally and three cruise line giants in particular.We believe cruise shares can continue to grind higher in the near term, driven overwhelmingly by the broader vaccine backdrop/progress. Looking out further, operators will face plenty of headwinds when restarting/ramping operations in 2Q3Q21, but significant sequential improvement of revenues/cash flows over that period will likely dominate the narrative, and we believe investors will continue to look through short-term setbacks to a 2022 characterized by fully ramped capacity, near-full occupancies, and so far manageable pricing pressure, Montour opined.Against this backdrop, Montour has picked out two stocks that are worth the risk, and one that investors should avoid for now. Using TipRanks Stock Comparison tool, we lined up the three alongside each other to get the lowdown on what the near-term holds for these cruise line players.Royal Caribbean (RCL)The second-largest cruise line, Royal Caribbean, remains a top pick for Montour and his firm. The company has put its resources into facing and meeting the pandemics challenges, shoring up liquidity and both streamlining and modernizing the fleet.Maintaining liquidity has been the most pressing issue. While the company has resumed some cruising, and has even taken delivery of a new ship, the Silver Moon, most operations remain